B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients

Oncology Letters

Volumn 8, Issue 3, 2014, Pages 1195-1201

  Baral, Aparajita ^a,b   Ye, Hong Xing ^b   Jiang, Pu Cha ^a   Yao, Yu ^b   Mao, Ying ^b,c  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

B7 family; B7 H1; B7 H3; Blood serum; Cerebral spinal fluid; Glioma

Indexed keywords

EID: 84904252086     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2268     Document Type: Article

References (28)

1. Chapoval AI, Ni J, Lau JS, et al: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2: 269, 2001.
2. Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
3. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H and Azuma M: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 105: 10495-10500, 2008.
4. Zhang G, Hou J, Shi J, Yu G, Lu B and Zhang X: Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 123: 538-546, 2008.
5. Sun J, Chen LJ, Zhang GB, et al: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 59: 1163-1171, 2010.
6. Merimsky O, Shoenfeld Y, Chaitchik S, Yecheskel G and Fishman P: Antigens and antibodies in malignant melanoma. Tumor Biol 15: 188-202, 1994.
7. Streit M and Detmar M: Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22: 3172-3179, 2003.
8. Miller AJ and Mihm MC Jr: Melanoma. N Engl J Med 355: 51-65, 2006.
9. Chen YW, Tekle C and Fodstad O: The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 8: 404-413, 2008.
10. Zang X, Sullivan PS, Soslow RA, et al: Tumor associated endothel expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23: 1104-1112, 2010.
11. Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151, 2006.
12. Wu CP, Jiang JT, Tan M, et al: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 12: 457-459, 2006.
13. Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900, 2007.
14. Yamato I, Sho M, Nomi T, et al: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 101: 1709-1716, 2009.
15. Loos M, Hedderich DM, Ottenhausen M, et al: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 9: 463, 2009.
16. Lemke D, Pfenning PN, Sahm F, et al: Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma mediating immune escape and invasiveness. Clin Cancer Res 18: 105-117, 2012.
17. Suh, WK, Gajewska BU, Okada H, et al: The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol 4: 899-906, 2003.
18. Luo L, Chapoval AI, Flies DB, et al: B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+cytolytic T cells. J Immunol 173: 5445-5450, 2004.
19. Ma L, Luo L, Qiao H, et al: Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 46: 98-106, 2007.
20. Geng L, Huang D, Liu J, et al: B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 134: 1021-1027, 2008.
21. Loos M, Giese NA, Kleeff J, et al: Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 268: 98-109, 2008.
22. Boorjian SA, Sheinin Y, Crispen PL, et al: T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14: 4800-4808, 2008.
23. Frigola X, Inman BA, Lohse CM, et al: Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 17: 1915-1923, 2011.
24. Rubin LL and Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci 22: 11-28, 1999.
25. Tseng SY, Otsuji M, Gorski K, et al: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193: 839-846, 2001.
26. Latchman Y, Wood CR, Chernova T, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261-268, 2001.
27. Yao Y, Tao R, Wang X, Wang Y, Mao Y and Zhou LF: B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells: Neuro Oncol 11: 757-766, 2009.
28. Chen X, Zhang G, Li Y, et al: Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. J Mol Neurosci 37: 86-94, 2009.